SELECTIVE INHIBITION OF THE MASTER REGULATOR TRANSCRIPTION FACTOR EGR-1 USING CATALYTIC OLIGONUCLEOTIDES REDUCES MYOCARDIAL INJURY AND IMPROVES LV SYSTOLIC FUNCTION IN A PRECLINICAL MODEL OF MYOCARDIAL INFARCTION